Wei E, Mitanoska A, OBrien Q, Porter K, Molina M, Ahsan H
Mol Cancer. 2024; 23(1):222.
PMID: 39367409
PMC: 11453018.
DOI: 10.1186/s12943-024-02115-7.
Su X, Stopsack K, Schmidt D, Ma D, Li Z, Scheet P
Proc Natl Acad Sci U S A. 2024; 121(36):e2405543121.
PMID: 39190349
PMC: 11388324.
DOI: 10.1073/pnas.2405543121.
Vanoli F, Antonescu C
Genes Chromosomes Cancer. 2023; 62(9):501-509.
PMID: 36965130
PMC: 10725040.
DOI: 10.1002/gcc.23141.
Molnar C, Reina J, Herrero A, Heinen J, Mendiz V, Bonnal S
PNAS Nexus. 2023; 1(4):pgac222.
PMID: 36714878
PMC: 9802468.
DOI: 10.1093/pnasnexus/pgac222.
Yu L, Davis I, Liu P
Cancers (Basel). 2023; 15(2).
PMID: 36672331
PMC: 9857208.
DOI: 10.3390/cancers15020382.
The importance of fusion protein activity in Ewing sarcoma and the cell intrinsic and extrinsic factors that regulate it: A review.
Apfelbaum A, Wrenn E, Lawlor E
Front Oncol. 2022; 12:1044707.
PMID: 36505823
PMC: 9727305.
DOI: 10.3389/fonc.2022.1044707.
Small round cell sarcomas.
Cidre-Aranaz F, Watson S, Amatruda J, Nakamura T, Delattre O, de Alava E
Nat Rev Dis Primers. 2022; 8(1):66.
PMID: 36202860
DOI: 10.1038/s41572-022-00393-3.
BRCA1-associated RING domain-1 (BARD1) loss and GBP1 expression enhance sensitivity to DNA damage in Ewing sarcoma.
Maurer L, Daley J, Mukherjee E, Venier R, Julian C, Bailey N
Cancer Res Commun. 2022; 2(4):220-232.
PMID: 36187937
PMC: 9524505.
DOI: 10.1158/2767-9764.crc-21-0047.
Prognosis and Outcome of Cervical Primary Extraosseous Intradural Extramedullary Ewing Sarcoma: A Systematic Review.
Carballo Cuello C, De Jesus O, de Jesus Espinosa A, Fernandez-de Thomas R, Murray G, Pastrana E
Cureus. 2022; 14(7):e26665.
PMID: 35959190
PMC: 9360665.
DOI: 10.7759/cureus.26665.
Latest developments in the pathobiology of Ewing sarcoma.
Karlina I, Schroeder B, Kirgizov K, Romantsova O, Istranov A, Nedorubov A
J Bone Oncol. 2022; 35:100440.
PMID: 35855933
PMC: 9287185.
DOI: 10.1016/j.jbo.2022.100440.
Epigenetic and Transcriptional Signaling in Ewing Sarcoma-Disease Etiology and Therapeutic Opportunities.
Li M, Chen C
Biomedicines. 2022; 10(6).
PMID: 35740349
PMC: 9219675.
DOI: 10.3390/biomedicines10061325.
Challenges in modeling EWS-FLI1-driven transgenic mouse model for Ewing sarcoma.
Ramachandran B, Rajkumar T, Gopisetty G
Am J Transl Res. 2021; 13(11):12181-12194.
PMID: 34956445
PMC: 8661172.
Extracellular Vesicles in Reprogramming of the Ewing Sarcoma Tumor Microenvironment.
Pachva M, Lai H, Jia A, Rouleau M, Sorensen P
Front Cell Dev Biol. 2021; 9:726205.
PMID: 34604225
PMC: 8484747.
DOI: 10.3389/fcell.2021.726205.
Unraveling Ewing Sarcoma Tumorigenesis Originating from Patient-Derived Mesenchymal Stem Cells.
Sole A, Grossetete S, Heintze M, Babin L, Zaidi S, Revy P
Cancer Res. 2021; 81(19):4994-5006.
PMID: 34341072
PMC: 8487988.
DOI: 10.1158/0008-5472.CAN-20-3837.
is a driver of chromosome 8 gain in Ewing sarcoma to mitigate replication stress.
Su X, Ma D, Parsons J, Replogle J, Amatruda J, Whittaker C
Genes Dev. 2021; 35(7-8):556-572.
PMID: 33766983
PMC: 8015718.
DOI: 10.1101/gad.345454.120.
An inducible ectopic expression system of EWSR1-FLI1 as a tool for understanding Ewing sarcoma oncogenesis.
Garcia-Dominguez D, Hontecillas-Prieto L, Leon E, Sanchez-Molina S, Rodriguez-Nunez P, Moron F
PLoS One. 2020; 15(6):e0234243.
PMID: 32502203
PMC: 7274397.
DOI: 10.1371/journal.pone.0234243.
Protein phosphatase 1 regulatory subunit 1A regulates cell cycle progression in Ewing sarcoma.
Luo W, Xu C, Phillips S, Gardenswartz A, Rosenblum J, Ayello J
Oncotarget. 2020; 11(19):1691-1704.
PMID: 32477459
PMC: 7233808.
DOI: 10.18632/oncotarget.27571.
Reconstruction of Ewing Sarcoma Developmental Context from Mass-Scale Transcriptomics Reveals Characteristics of EWSR1-FLI1 Permissibility.
Miller H, Gorthi A, Bassani N, Lawrence L, Iskra B, Bishop A
Cancers (Basel). 2020; 12(4).
PMID: 32290418
PMC: 7226175.
DOI: 10.3390/cancers12040948.
Development of an Ewing sarcoma cell line with resistance to EWS‑FLI1 inhibitor YK‑4‑279.
Conn E, Hour S, Allegakoen D, Graham G, Petro J, Kouassi-Brou M
Mol Med Rep. 2020; 21(3):1667-1675.
PMID: 32016454
PMC: 8371434.
DOI: 10.3892/mmr.2020.10948.
Targeting the undruggable: exploiting neomorphic features of fusion oncoproteins in childhood sarcomas for innovative therapies.
Knott M, Holting T, Ohmura S, Kirchner T, Cidre-Aranaz F, Grunewald T
Cancer Metastasis Rev. 2020; 38(4):625-642.
PMID: 31970591
PMC: 6994515.
DOI: 10.1007/s10555-019-09839-9.